The aim of the work was a retrospective comparison of the clinical course of acute myocardial infarction depending on the applied schema of pharmacological treatment: streptokinase, heparin, antiplatelet drugs. The analysis included 409 patients (261 men and 148 women aged 31-85 years; mean age 61 years). Twelve-lead ECG records were analysed: 24 hours, 48 hours, 72 hours, 7 days and 14 days after the onset of the disease. The sum of ST segment elevations, sum of Q wave amplitude and the sum of R wave amplitude in the leads showing signs of infarction were taken into account. The mean was calculated from the highest values of AspAT and AlAT. The haemodynamic, arrhythmic and other early and late complications occurring during the treatment were subjected to analysis; the per cent index of deaths in each group was also calculated. In the patients treated with streptokinase, in comparison to the patients treated with heparin and antiplatelet drugs, earliest stabilization was observed of the ECG pattern in the form of: reduction of ST segment elevation, reduction of R wave height, and formation of a stable Q wave. AspAT and AlAT values were highest in the group of patients treated with streptokinase in relation to the remaining groups of patients. Arrhythmic and haemodynamic complications occurred less frequently in the patients treated with streptokinase and heparin than in those treated with antiplatelet drugs. On the other hand, late and other early complications were observed less frequently in the patients treated with antiplatelet drugs. The mortality during hospitalization period was similar in individual groups of patients, being 7.2% for the patients treated with streptokinase, 7.5% for those treated with antiplatelet drugs, and 9% for those treated with heparin.
Download full-text PDF |
Source |
---|
J Bone Miner Res
January 2025
Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
We previously documented successful resolution of skeletal and dental disease in the infantile and late-onset murine models of hypophosphatasia (HPP), with a single injection of an adeno-associated serotype 8 vector encoding mineral-targeted TNAP (AAV8-TNAP-D10). Here, we conducted dosing studies in both HPP mouse models. A single escalating dose from 4x108 up to 4x1010 (vg/b) was intramuscularly injected into 4-day-old Alpl-/- mice (an infantile HPP model) and a single dose from 4x106 up to 4x109 (vg/b) was administered to 8-week-old AlplPrx1/Prx1 mice (a late-onset HPP model).
View Article and Find Full Text PDFDrug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFClin J Gastroenterol
January 2025
Department of Surgery, Shizuoka Medical Center NHO, 762-1, Nagasawa, Shimizu, Sunto, Shizuoka, 411-8611, Japan.
Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) of the colon is rare with a poor prognosis. Since the first description of a mixed neoplasm 100 years ago, the nomenclature has evolved, most recently with the 2022 World Health Organization (WHO) classification system. We describe our experience of a case of locoregionally advanced MiNEN of the descending colon treated with curative laparoscopic resection and adjuvant chemotherapy.
View Article and Find Full Text PDFJ Nephrol
January 2025
School of Life and Medical Sciences, University of Hertfordshire, College Lane Campus, Hatfield, UK.
Breast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!